Who is affected by this change?

This affects Arkansas Blue Cross Blue Shield Infectious Disease, Internal Medicine, Family Medicine providers in AR on Commercial plans.

When does this change take effect?

This change is effective May 6, 2026.

Which billing codes are affected?

The following codes are affected: J0750, J0751, J0752.

Back to dashboard

CommercialCoverageLow impact

Policy Criteria Change

Arkansas Blue Cross Blue Shield·AR · Infectious Disease, Internal Medicine, Family Medicine·Medical Policy

Effective date

May 6, 2026

We identified it

Jun 19, 2026

Days to comply

—

Summary

Arkansas Blue Cross is archiving the Fidanacogene elaparvovec-dzkt (Beqvez) policy due to Pfizer discontinuing the drug, and adding three new HCPCS codes (J0750, J0751, J0752) to the self-administered medication list for PrEP antiretroviral therapy. PrEP medications will be covered at no cost-share through pharmacy benefits.

Action Required

Action needed

By May 6, 2026: Billing team must update system to recognize new HCPCS codes J0750, J0751, and J0752 as self-administered medications covered through pharmacy benefit with no cost-share. Remove Fidanacogene elaparvovec-dzkt (Beqvez) from formulary lists as the drug has been discontinued.

Affected Billing Codes

J0750

J0751

J0752

Related policy hubs

Arkansas Blue Cross Blue Shield policies AR policy changes Infectious Disease Internal Medicine Family Medicine Code J0750 Code J0751 Code J0752